Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,530 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and efficacy of vorinostat, bortezomib, doxorubicin and dexamethasone in a phase I/II study for relapsed or refractory multiple myeloma (VERUMM study: vorinostat in elderly, relapsed and unfit multiple myeloma).
Waldschmidt JM, Keller A, Ihorst G, Grishina O, Müller S, Wider D, Frey AV, King K, Simon R, May A, Tassone P, Duyster J, Jung M, Raje N, Wäsch R, Engelhardt M. Waldschmidt JM, et al. Among authors: may a. Haematologica. 2018 Oct;103(10):e473-e479. doi: 10.3324/haematol.2018.189969. Epub 2018 Apr 19. Haematologica. 2018. PMID: 29674494 Free PMC article. Clinical Trial. No abstract available.
Cytogenetics of extramedullary manifestations in multiple myeloma.
Billecke L, Murga Penas EM, May AM, Engelhardt M, Nagler A, Leiba M, Schiby G, Kröger N, Zustin J, Marx A, Matschke J, Tiemann M, Goekkurt E, Heidtmann HH, Vettorazzi E, Dierlamm J, Bokemeyer C, Schilling G. Billecke L, et al. Among authors: may am. Br J Haematol. 2013 Apr;161(1):87-94. doi: 10.1111/bjh.12223. Epub 2013 Feb 1. Br J Haematol. 2013. PMID: 23368088 Free article.
ID2 and ID3 protein expression mirrors granulopoietic maturation and discriminates between acute leukemia subtypes.
May AM, Frey AV, Bogatyreva L, Benkisser-Petersen M, Hauschke D, Lübbert M, Wäsch R, Werner M, Hasskarl J, Lassmann S. May AM, et al. Histochem Cell Biol. 2014 Apr;141(4):431-40. doi: 10.1007/s00418-013-1169-7. Epub 2013 Nov 30. Histochem Cell Biol. 2014. PMID: 24292846

Moreover, differential ID2/3 expression was seen between AL subgroups: AML, especially AML-MD, had more ID2- (p < 0.001) and ID3-positive (p < 0.001) blasts than ALL. We show a comprehensive in situ picture of ID2/3 expression in hematopoiesis and AL. ...Importantly,

…

Moreover, differential ID2/3 expression was seen between AL subgroups: AML, especially AML-MD, had more ID2- (p < 0.001) and ID3-positive

…
DECIDER: prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients >60 years with acute myeloid leukemia who are ineligible for induction chemotherapy.
Grishina O, Schmoor C, Döhner K, Hackanson B, Lubrich B, May AM, Cieslik C, Müller MJ, Lübbert M. Grishina O, et al. BMC Cancer. 2015 May 26;15:430. doi: 10.1186/s12885-015-1432-5. BMC Cancer. 2015. PMID: 26008690 Free PMC article. Clinical Trial.
Large registry analysis to accurately define second malignancy rates and risks in a well-characterized cohort of 744 consecutive multiple myeloma patients followed-up for 25 years.
Engelhardt M, Ihorst G, Landgren O, Pantic M, Reinhardt H, Waldschmidt J, May AM, Schumacher M, Kleber M, Wäsch R. Engelhardt M, et al. Haematologica. 2015 Oct;100(10):1340-9. doi: 10.3324/haematol.2015.127548. Epub 2015 Jul 9. Haematologica. 2015. PMID: 26160877 Free PMC article.
Cytogenetics in patients acquiring second primary malignancies were predominantly favorable, suggesting that indolent myeloma and long disease latency may allow the manifestation of additional malignancies. An assessment of the Surveillance, Epidemiology, and End Result Pr …
Cytogenetics in patients acquiring second primary malignancies were predominantly favorable, suggesting that indolent myeloma and long disea …
Decitabine in combination with donor lymphocyte infusions can induce remissions in relapsed myeloid malignancies with higher leukemic burden after allogeneic hematopoietic cell transplantation.
Sommer S, Cruijsen M, Claus R, Bertz H, Wäsch R, Marks R, Zeiser R, Bogatyreva L, Blijlevens NMA, May A, Duyster J, Huls G, van der Velden WJFM, Finke J, Lübbert M. Sommer S, et al. Among authors: may a. Leuk Res. 2018 Sep;72:20-26. doi: 10.1016/j.leukres.2018.07.005. Epub 2018 Jul 7. Leuk Res. 2018. PMID: 30064039 Clinical Trial.
2,530 results